RT Journal Article SR Electronic T1 Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 1624 OP 1625 VO 30 IS 7 A1 Marc Michel A1 Cristophe Duvoux A1 Cristophe Hezode A1 Daniel Cherqui YR 2003 UL http://www.jrheum.org/content/30/7/1624.abstract AB Infliximab, a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, has been demonstrated to be efficient and safe in patients with active rheumatoid arthritis and in the management of severe bouts of Crohn's disease. However, the safety of infliximab has not been evaluated in patients infected with hepatitis B virus. We report the case of a 28-year-old woman, with a positive hepatitis B virus surface antigen, who developed fulminant hepatitis 2 weeks after receiving a second infliximab infusion for a refractory adult onset Still's disease.